Last reviewed · How we verify
Iron Carboxymaltose
Iron carboxymaltose delivers iron directly into the bloodstream as a stable iron-carbohydrate complex that is taken up by iron-binding proteins to replenish depleted iron stores.
Iron carboxymaltose delivers iron directly into the bloodstream as a stable iron-carbohydrate complex that is taken up by iron-binding proteins to replenish depleted iron stores. Used for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron, Perioperative iron deficiency anemia.
At a glance
| Generic name | Iron Carboxymaltose |
|---|---|
| Also known as | Ferinject®, IRON, Ferinject, Ferrous Carboxymaltose |
| Sponsor | Albina Nowak, MD |
| Drug class | Intravenous iron replacement agent |
| Target | Iron(III) ion; transferrin and ferritin (iron-binding proteins) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Iron carboxymaltose is an intravenous iron replacement therapy that consists of iron(III) bound to a carbohydrate shell (carboxymaltose). The complex protects iron from premature release and allows controlled uptake by transferrin and ferritin, enabling rapid and safe iron repletion without the gastrointestinal side effects associated with oral iron supplements. It is particularly useful in patients with iron deficiency anemia who cannot tolerate or absorb oral iron.
Approved indications
- Iron deficiency anemia in patients with chronic kidney disease
- Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron
- Perioperative iron deficiency anemia
Common side effects
- Injection site reactions (pain, discoloration)
- Headache
- Nausea
- Dizziness
- Hypophosphatemia
- Hypersensitivity reactions
Key clinical trials
- Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
- The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department (PHASE4)
- EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY (PHASE1)
- The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension (PHASE4)
- Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation (PHASE4)
- Comparison of Oral vs Intravenous Iron Therapy for the Treatment of Postpartum Anemia (NA)
- Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency (PHASE3)
- An Open Study on the Efficacy of Iron Therapy Using iv Iron Relative to Oral Iron for Increasing LV Systolic Function (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron Carboxymaltose CI brief — competitive landscape report
- Iron Carboxymaltose updates RSS · CI watch RSS
- Albina Nowak, MD portfolio CI